BUSINESS

Mochida Files Inhaled Treprostinil for PAH in Japan

February 7, 2022

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Mochida Pharmaceutical said on February 4 that it has filed a new drug application in Japan for an inhaled version of treprostinil, which is currently available in injection forms, for the treatment of pulmonary arterial hypertension (PAH). The inhaled drug,…

To read the full story

Mochida’s Inhaled Treprostinil Gets Orphan Status
December 22, 2021
Mochida Gets Japan Distribution Rights to Tyvaso
March 29, 2017

BUSINESS

Moderna Japan Looks Beyond COVID for Next Growth Pillars
June 9, 2026
Oncolys Targets 300 Hospitals for Telomelysin Rollout
June 9, 2026
CSL Behring Japan President Yoshida to Step Down
June 8, 2026
Japan Approves Oncolys’ Telomelysin for Esophageal Cancer
June 8, 2026
Takeda Swings to Loss after Booking Amitiza Litigation Charge
June 8, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…